Share on StockTwits

Investment analysts at Aegis raised their target price on shares of Medivation (NASDAQ:MDVN) from $125.00 to $130.00 in a note issued to investors on Friday. Aegis’ price target suggests a potential upside of 60.63% from the company’s current price.

Shares of Medivation (NASDAQ:MDVN) traded up 7.52% during mid-day trading on Friday, hitting $80.93. The stock had a trading volume of 4,068,640 shares. Medivation has a one year low of $48.15 and a one year high of $88.20. The stock has a 50-day moving average of $75.89 and a 200-day moving average of $71.59. The company’s market cap is $6.193 billion. Medivation also was the target of some unusual options trading on Friday. Stock traders acquired 861 call options on the stock. This represents an increase of approximately 295% compared to the typical volume of 218 call options.

Medivation (NASDAQ:MDVN) last announced its earnings results on Thursday, August 7th. The company reported $0.60 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.24 by $0.36. The company had revenue of $148.09 million for the quarter, compared to the consensus estimate of $126.46 million. During the same quarter last year, the company posted ($0.07) earnings per share. Medivation’s revenue was up 111.1% compared to the same quarter last year. On average, analysts predict that Medivation will post $1.50 earnings per share for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at Leerink Swann raised their price target on shares of Medivation from $104.00 to $107.00 in a research note on Friday. Separately, analysts at Keefe, Bruyette & Woods reiterated an “outperform” rating on shares of Medivation in a research note on Friday. They now have a $107.00 price target on the stock, up previously from $104.00. Finally, analysts at Stifel Nicolaus raised their price target on shares of Medivation from $83.00 to $89.00 in a research note on Friday. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $96.47.

Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.